deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT04639310

XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic Encephalopathy (EPIK)

A Phase 3 Study of Adjunctive XEN496 in Pediatric Subjects With KCNQ2 Developmental and Epileptic Encephalopathy

Sponsor: Xenon Pharmaceuticals Inc.

Conditions Brain Diseases Central Nervous System Diseases Disease Epilepsy Epilepsy in Children Epilepsy; Seizure Epileptic Syndromes Nervous System Diseases
Interventions Placebo XEN496
Updated 14 times since 2020 Last updated: Aug 21, 2024 Started: Mar 29, 2021 Primary completion: May 16, 2023 Completion: May 16, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision; Not a safety decision

Other terminated trials from Xenon Pharmaceuticals Inc.

More terminations from Xenon Pharmaceuticals Inc.

Other Brain Diseases trials with similar outcome

Browse all Brain Diseases trials

Listed as NCT04639310, this PHASE3 trial focuses on Brain Diseases and Central Nervous System Diseases and remains terminated or withdrawn. Sponsored by Xenon Pharmaceuticals Inc., it has been updated 14 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Jun 2021 · 5 months · monthly snapshot~Jun 2021 – ~Sep 2021 · 3 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Nov 2021 · 31 days · monthly snapshot~Nov 2021 – ~Sep 2022 · 10 months · monthly snapshot~Sep 2022 – ~Dec 2022 · 3 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshot~Feb 2023 – ~Jul 2023 · 5 months · monthly snapshot~Jul 2023 – ~Jul 2024 · 12 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  4. Jul 2023 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: Recruiting → Terminated

  5. Feb 2023 — Jul 2023 [monthly]

    Recruiting PHASE3

▶ Show 9 earlier versions

  1. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE3

  2. Dec 2022 — Jan 2023 [monthly]

    Recruiting PHASE3

  3. Sep 2022 — Dec 2022 [monthly]

    Recruiting PHASE3

  4. Nov 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  5. Oct 2021 — Nov 2021 [monthly]

    Recruiting PHASE3

  6. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE3

  7. Jun 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  8. Jan 2021 — Jun 2021 [monthly]

    Not Yet Recruiting PHASE3

  9. Dec 2020 — Jan 2021 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Xenon Pharmaceuticals Inc.
Data source: Xenon Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aurora, United States , Chicago, United States , Cleveland, United States , Edegem, Belgium , Esplugues de Llobregat, Spain , Genova, Italy , Gulf Breeze, United States , Heidelberg, Australia , Madrid, Spain , Milan, Italy and 10 more locations